BMS’ Opdivo cleared for monthly use

7th March 2018 Uncategorised 0

US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks.

More: BMS’ Opdivo cleared for monthly use
Source: News